Emerging clinical role of proprotein convertase subtilisin/kexin type 9 inhibition—Part one: Pleiotropic pro‐atherosclerotic effects of PCSK9

Documenti analoghi

• Proprotein convertase subtilisin/kexin type 9 (PCSK9) and clinical outcomes in dialysis patients
  di: Claudia Torino, et al.
  Pubblicazione: (2024)
• Proprotein convertase subtilisin/kexin type 9 (PCSK9) and clinical outcomes in patients with end‐stage renal disease
  di: Johann Auer, et al.
  Pubblicazione: (2024)
• Lipoprotein(a) in clinical practice: Risk stratification and therapeutic strategies
  di: Nadim Nasrallah, et al.
  Pubblicazione: (2025)
• The biology of lipoprotein(a): From genetics to molecular mechanisms
  di: Mark Atallah, et al.
  Pubblicazione: (2025)
• Regression of carotid atherosclerosis in high‐risk individuals with proprotein convertase subtilisin/kexin type 9 inhibitors
  di: Albert Z. Luu, et al.
  Pubblicazione: (2025)